Global Briefs: Eisai & Neurocrine Biosciences

* Eisai Opens New US HQ in New Jersey
* Neurocrine Biosciences To Acquire Diurnal for $57 M

Eisai Opens US HQ in New Jersey
Eisai Inc., the US subsidiary of the Tokyo-based bio/pharmaceutical company, Eisai Co., has opened its new US headquarters in Nutley, New Jersey. The new 332,800-square-foot facility brings approximately 800 jobs to the Nutley–Clifton area in New Jersey and, at full capacity, will accommodate 1,300 employees. The company’s presence in the US includes two discovery centers as well as commercial, clinical development, and global demand organizations.

Source: Eisai

Neurocrine Biosciences To Acquire Diurnal in $57-M Deal
Neurocrine Biosciences, a San Diego, California-based pharmaceutical company developing small molecules for neurological and endocrine-related disorders, has agreed to acquire Diurnal Group, a Cardiff, UK-headquartered specialty pharmaceutical company targeting chronic endocrine diseases, in a deal worth up to £48.3 million ($56.5 million).

The transaction is conditional on, among other things, the approval of Diurnal shareholders.

Source: Neurocrine Biosciences